DMG-ACT — Advancing Multi-Modality, Precision-Driven Treatment

DMG-ACT (Diffuse Midline Glioma – Adaptive Combinatorial Therapy) is a global, multidisciplinary initiative transforming how children with DIPG and DMG are treated. Built on the belief that no single therapy will defeat these heterogeneous and aggressive tumors, DMG-ACT brings together world-leading clinicians, scientists, and institutions to rapidly identify, test, and advance the most promising treatment combinations for children battling these cancers.

In 2026, ChadTough Defeat DIPG Foundation’s support of DMG-ACT enables a decisive expansion into multi-modality treatment strategies designed to address DMG from multiple biological angles. Building on insights generated through PNOC022, the platform is advancing new adaptive arms that integrate targeted therapy, metabolic intervention, immunotherapy, and oncolytic approaches.

Key initiatives funded in 2026 include Cohort 6, evaluating repeated intratumoral delivery of the oncolytic virus DNX-2401 in combination with ONC201, and the development of Cohort 7, which combines ONC201 with atorvastatin and levetiracetam—three FDA-approved agents selected based on converging preclinical and clinical evidence. These strategies aim to improve durability of response while maintaining feasibility for rapid clinical implementation.

Equally important, 2026 funding supports continued investment in correlative science and biomarker integration, laying the groundwork for DMG-ACT Platform Trial 2.0. This next-generation framework brings together radiation, targeted therapies, immunotherapy, and maintenance strategies within a unified adaptive design—reflecting a new era of precision-driven clinical research for DMG.

The ChadTough Defeat DIPG Foundation has been a committed supporter of DMG-ACT since 2020.